Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016, Article ID 5143071, 9 pages
http://dx.doi.org/10.1155/2016/5143071
Research Article

Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation

1Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan
2Faculty of Medicine, National Yang-Ming University, Taipei 11221, Taiwan
3Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taitung Branch, Taitung City, Taitung County 95059, Taiwan
4Institute of Clinical Medicine, National Yang-Ming University, Taipei 11221, Taiwan
5Department of Ophthalmology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
6Department of Medicine, Cardinal Tien Hospital, New Taipei City 23148, Taiwan

Received 2 December 2015; Revised 12 February 2016; Accepted 25 February 2016

Academic Editor: Jenny Persson

Copyright © 2016 Yao-Chung Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. J. Thomson and K. S. Peggs, “Allogeneic transplantation in the UK: an aggregation of marginal gains?” British Journal of Haematology, vol. 163, no. 2, pp. 149–159, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Vyas, F. R. Appelbaum, and C. Craddock, “Allogeneic hematopoietic cell transplantation for acute myeloid leukemia,” Biology of Blood and Marrow Transplantation, vol. 21, no. 1, pp. 8–15, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. R. J. Soiffer, J. LeRademacher, V. Ho et al., “Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies,” Blood, vol. 117, no. 25, pp. 6963–6970, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. E. P. Alyea, H. T. Kim, V. Ho et al., “Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age,” Blood, vol. 105, no. 4, pp. 1810–1814, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. de Lima, A. Anagnostopoulos, M. Munsell et al., “Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation,” Blood, vol. 104, no. 3, pp. 865–872, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. C. N. Bredeson, M.-J. Zhang, M.-A. Agovi et al., “Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide,” Biology of Blood and Marrow Transplantation, vol. 14, no. 9, pp. 993–1003, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J.-H. Lee, Y.-D. Joo, H. Kim et al., “Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine,” Journal of Clinical Oncology, vol. 31, no. 6, pp. 701–709, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. Y.-C. Liu, J.-P. Gau, Y.-C. Hong et al., “Large pericardial effusion as a life-threatening complication after hematopoietic stem cell transplantation-association with chronic GVHD in late-onset adult patients,” Annals of Hematology, vol. 91, no. 12, pp. 1953–1958, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. Y.-C. Liu, S.-H. Chien, N.-W. Fan et al., “Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation,” British Journal of Haematology, vol. 169, no. 5, pp. 737–745, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. Y.-C. Liu, S.-H. Chien, N.-W. Fan et al., “Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation,” Journal of Microbiology, Immunology and Infection, 2015. View at Publisher · View at Google Scholar
  11. A. H. Groll, E. Castagnola, S. Cesaro et al., “Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation,” The Lancet Oncology, vol. 15, no. 8, pp. e327–e340, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Ljungman, R. Brand, J. Hoek et al., “Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation,” Clinical Infectious Diseases, vol. 59, no. 4, pp. 473–481, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Gratwohl, “The EBMT risk score,” Bone Marrow Transplantation, vol. 47, no. 6, pp. 749–756, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. A. J. Sankoh, H. Li, and S. D'Agostino, “Use of composite endpoints in clinical trials,” Statistics in Medicine, vol. 33, no. 27, pp. 4709–4714, 2014. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  15. J. Bolanos-Meade, J. Koreth, and R. Reshef, “A multicenter phase II trial randomizing novel approaches for graft-versus-host disease prevention compared to contemporary controls (BMT CTN 1203),” 2015, https://clinicaltrials.gov/ct2/show/NCT02208037.
  16. S. G. Holtan, T. E. DeFor, A. Lazaryan et al., “Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation,” Blood, vol. 125, no. 8, pp. 1333–1338, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. M.-H. Chen, P.-C. Chen, S.-F. Jeng et al., “High perinatal seroprevalence of cytomegalovirus in northern Taiwan,” Journal of Paediatrics and Child Health, vol. 44, no. 4, pp. 166–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. E. D. Thomas, R. Storb, R. A. Clift et al., “Bone-marrow transplantation (second of two parts),” New England Journal of Medicine, vol. 292, no. 17, pp. 895–902, 1975. View at Publisher · View at Google Scholar · View at Scopus
  19. A. H. Filipovich, D. Weisdorf, S. Pavletic et al., “National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report,” Biology of Blood and Marrow Transplantation, vol. 11, no. 12, pp. 945–956, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Gratwohl, J. Hermans, J. M. Goldman et al., “Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation,” The Lancet, vol. 352, no. 9134, pp. 1087–1092, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. J. O. Armitage, “Bone marrow transplantation,” The New England Journal of Medicine, vol. 330, no. 12, pp. 827–838, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Sierra, B. Storer, J. A. Hansen et al., “Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose,” Blood, vol. 89, no. 11, pp. 4226–4235, 1997. View at Google Scholar · View at Scopus
  23. A. Gratwohl, M. Stern, R. Brand et al., “Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis,” Cancer, vol. 115, no. 20, pp. 4715–4726, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Rezvani, E. J. Kanfer, D. Marin et al., “EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure,” Biology of Blood and Marrow Transplantation, vol. 18, no. 2, pp. 235–240, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. T. H. Terwey, P. G. Hemmati, P. Martus et al., “A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia,” Haematologica, vol. 95, no. 5, pp. 810–818, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Lodewyck, M. Oudshoorn, B. van der Holt et al., “Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia,” Leukemia, vol. 25, no. 10, pp. 1548–1554, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Jalali, K. Alimoghaddam, M. Mahmoudi et al., “The EBMT risk score in the presence of graft versus host disease in allogeneic stem cell transplantation in adult acute myelogenous leukemia: a multistate model for competing risks,” International Journal of Hematology-Oncology and Stem Cell Research, vol. 8, no. 3, pp. 1–11, 2014. View at Google Scholar · View at Scopus
  28. J. Liu, J. Kong, Y. J. Chang et al., “Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality,” Clinical Microbiology and Infection, vol. 21, no. 12, pp. 1121.e9–1121.e15, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Ljungman, M. Hakki, and M. Boeckh, “Cytomegalovirus in hematopoietic stem cell transplant recipients,” Infectious Disease Clinics of North America, vol. 24, no. 2, pp. 319–337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Ljungman, “The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation,” Current Opinion in Hematology, vol. 21, no. 6, pp. 466–469, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. B. K. Hamilton, A. D. Law, L. Rybicki et al., “Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients,” Bone Marrow Transplantation, vol. 50, no. 9, pp. 1235–1240, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. M. C. Pasquini, Z. Wang, and M. M. Horowitz, “2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders,” Clinical Transplants, pp. 87–105, 2010. View at Google Scholar
  33. U. Holtick, M. Albrecht, J. M. Chemnitz et al., “Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults-a systematic review and meta-analysis,” Critical Reviews in Oncology/Hematology, vol. 94, no. 2, pp. 179–188, 2015. View at Publisher · View at Google Scholar · View at Scopus